- Home
- FTRE
as 04-22-2025 4:00pm EST
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 483.5M | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.77 - $38.04 | Next Earning Date: | 05-12-2025 |
| Revenue: | $2,696,400,000 | Revenue Growth: | -5.14% |
| Revenue Growth (this year): | -5.54% | Revenue Growth (next year): | 3.38% |
Stock Insider Trading Activity of Fortrea Holdings Inc. (FTRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mcconnell Jill G. | FTRE | Chief Financial Officer | Mar 13 '25 | Sell | $9.70 | 1,210 | $11,737.00 | 40,467 | |
| Morais Mark A. | FTRE | Chief Operating Officer | Mar 13 '25 | Sell | $9.70 | 1,207 | $11,707.90 | 38,672 | |
| Hanson James S. | FTRE | General Counsel | Mar 13 '25 | Sell | $9.70 | 1,007 | $9,767.90 | 9,466 | |
| Mcconnell Jill G. | FTRE | Chief Financial Officer | Mar 12 '25 | Sell | $9.93 | 261 | $2,591.73 | 40,467 | |
| Morais Mark A. | FTRE | Chief Operating Officer | Mar 12 '25 | Sell | $9.93 | 203 | $2,015.79 | 38,672 | |
| Mcconnell Jill G. | FTRE | Chief Financial Officer | Mar 11 '25 | Sell | $9.98 | 643 | $6,417.14 | 40,467 | |
| Morais Mark A. | FTRE | Chief Operating Officer | Mar 11 '25 | Sell | $9.98 | 499 | $4,980.02 | 38,672 | |
| Mcconnell Jill G. | FTRE | Chief Financial Officer | Feb 11 '25 | Sell | $14.67 | 540 | $7,921.80 | 40,467 | |
| Morais Mark A. | FTRE | Chief Operating Officer | Feb 11 '25 | Sell | $14.67 | 424 | $6,220.08 | 38,672 | |
| Mcconnell Jill G. | FTRE | Chief Financial Officer | Feb 7 '25 | Sell | $14.80 | 578 | $8,554.40 | 40,467 |
Latest Fortrea Holdings Inc. News
FTRE Breaking Stock News: Dive into FTRE Ticker-Specific Updates for Smart Investing
Argus Research
8 days ago
FTRE: Lowering target price to $5.00
GlobeNewswire
8 days ago
Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call
Argus Research
15 days ago
FTRE: Rating decreased to a HOLD
Argus Research
22 days ago
FTRE: Lowering target price to $8.00
Argus Research
a month ago
FTRE: Lowering target price to $10.00
Morningstar Research
a month ago
Analyst Report: Fortrea Holdings Inc.
Argus Research
2 months ago
FTRE: Lowering target price to $12.00
GuruFocus.com
2 months ago
Fortrea Holdings Inc (FTRE) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...
Compare FTRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FTRE Fortrea Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.